California's Stem Cell Agency Awards Fate Therapeutics $15 Million To Run A Mid-Stage Lupus Kidney Trial

The California Institute for Regenerative Medicine awarded Fate Therapeutics a $15 million grant on Friday through its competitive CLIN2 program to advance a mid-stage trial of FT819, the company's off-the-shelf CAR T-cell therapy, in patients with a severe form of lupus that affects roughly 150,000 Americans. The award was disclosed in an 8-K filed Monday with the SEC.

What The Filing Says

The grant supports RECLAIM-LN, a mid-stage, open-label, single-arm trial designed to enroll about 53 patients with refractory moderate-to-severe systemic lupus erythematosus with kidney involvement — specifically Class III or IV lupus nephritis, with or without concomitant Class V. Every patient must have failed at least two prior systemic immunosuppressive therapies before enrolling.

The main goal of the trial is the proportion of patients achieving complete renal response at week 26. Secondary measures include disease activity scores and quality-of-life assessments.

FT819 carries FDA Regenerative Medicine Advanced Therapy designation, and the agency developed the RECLAIM-LN study design through interactions with Fate under that designation. The therapy has also been selected for the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot program, which gives companies on accelerated timelines earlier and more frequent communication with the agency on manufacturing readiness.

The Disease And The Drug's Design

Lupus nephritis — kidney inflammation driven by systemic lupus erythematosus — is a leading cause of kidney failure among lupus patients. Existing immunosuppressive options leave a substantial share of those patients without adequate disease control, according to the press release.

FT819 targets CD19, a protein on the surface of the B cells that drive lupus pathology, aiming to deliver deep and durable depletion of those cells. What distinguishes it from conventional CAR T-cell therapies — which are made from a patient's own cells — is its manufacturing origin: FT819 is produced from a precisely engineered clonal master induced pluripotent stem cell bank, the same concept used to mass-produce biopharmaceutical drugs such as monoclonal antibodies. That approach yields a uniform, well-defined product that can be stored in inventory and administered on demand, without the weeks-long manufacturing lead time that patient-derived therapies require.

The practical consequence, the company says, is that FT819 can be given as an outpatient treatment in community settings — extending access beyond the specialized academic centers that typically administer conventional CAR T-cell therapies. The company also says patients may be able to discontinue standard immunosuppressive therapies after treatment.

Early Data And The Grant's Competitive Weight

Preliminary results from the earlier-stage study of FT819 showed favorable safety and tolerability alongside clinically meaningful reductions in disease activity scores — measured by the clinical Systemic Lupus Erythematosus Disease Activity Index — and in urine protein-to-creatinine ratio, a marker of kidney damage. Both measures improved further when a less-intensive conditioning regimen using bendamustine was used instead of the standard approach.

CIRM's CLIN2 program is designed specifically to fund clinical-stage therapies with transformative potential, and its review process involves detailed scientific evaluation by expert panels. Beyond the cash, CIRM commits internal staff and a network of subject-matter experts to help funded programs build a development strategy aimed at marketing approval and patient access.

Sohel Talib, PhD, Senior Fellow in Clinical Development at CIRM, said the award "represents a significant step forward in transforming the clinical practice for patients living with a severe form of lupus" and that the study would evaluate "off-the-shelf immediately available CAR T-cell therapy with the ability to broaden the accessibility of this potentially curative therapy to patients who otherwise would not have access."

Bob Valamehr, President and Chief Executive Officer of Fate Therapeutics, said the company is "honored" that CIRM recognized FT819's potential "to treat large number of these patients in need, including in underserved regions," and described the grant as supporting the company's "commitment to making CAR T-cell therapy broadly accessible."

FATE shares edged up about 0.43% to $2.31 in Friday trading, according to market data.

What To Watch

The next meaningful signals from RECLAIM-LN will be interim enrollment and safety data as the trial advances. Also worth tracking: any FDA interactions under FT819's Regenerative Medicine Advanced Therapy designation that could shape the timeline and requirements for a potential marketing application.

The 8-K, signed by Valamehr and filed Monday, identifies the grant numbers as CLIN2-16303 and CLIN2-20291 — the two CIRM awards that have now collectively backed FT819's clinical development.

Sources

• 8-K Filing — FATE THERAPEUTICS INC (FATE) — SEC EDGAR
• Exhibit fate-ex99_1.htm — FATE THERAPEUTICS INC 8-K exhibit — SEC EDGAR
• Fate Therapeutics Reports New Employee Inducement Awards — globenewswire.com
• Fate Therapeutics Announces Receipt of California Institute — globenewswire.com